AN2 Therapeutics (ANTX) Shares Outstanding (Weighted Average) (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $34.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $34.1 million, up 13.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.1 million (up 13.33% YoY), and the FY2025 annual result was $30.2 million, up 1.3% from the prior year.
• Shares Outstanding (Weighted Average) rose to $34.1 million in Q1 2026 per ANTX's latest filing, from $30.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $34.1 million in Q1 2026 and troughed at $3.2 million in Q1 2022.
• A 5-year average of $23.9 million and a median of $29.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) surged 509.47% in 2023, then rose 0.97% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $15.3 million in 2022, then surged by 53.85% to $23.6 million in 2023, then climbed by 26.39% to $29.8 million in 2024, then advanced by 1.3% to $30.2 million in 2025, then advanced by 12.72% to $34.1 million in 2026.
• Business Quant data shows ANTX's Shares Outstanding (Weighted Average) at $34.1 million in Q1 2026, $30.2 million in Q4 2025, and $30.3 million in Q3 2025.